Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Arana A, Cuchi T, Arellano F. Strengthening EU pharmacovigilance. European pharmaceutical contractor. European pharmaceutical contracto: EPC. 2009;44-5.